Literature DB >> 17029348

A review of current and future medical therapies for cerebral vasospasm following aneurysmal subarachnoid hemorrhage.

J Mocco1, Brad E Zacharia, Ricardo J Komotar, E Sander Connolly.   

Abstract

In an effort to help clarify the current state of medical therapy for cerebral vasospasm, the authors reviewed the relevant literature on the established medical therapies used for cerebral vasospasm following aneurysmal subarachnoid hemorrhage (SAH), and they discuss burgeoning areas of investigation. Despite advances in the treatment of aneurysmal SAH, cerebral vasospasm remains a common complication and has been correlated with a 1.5- to threefold increase in death during the first 2 weeks after hemorrhage. A number of medical, pharmacological, and surgical therapies are currently in use or being investigated in an attempt to reverse cerebral vasospasm, but only a few have proven to be useful. Although much has been elucidated regarding its pathophysiology, the treatment of cerebral vasospasm remains a dilemma. Although a poor understanding of SAH-induced cerebral vasospasm pathophysiology has, to date, hampered the development of therapeutic interventions, current research efforts promise the eventual production of new medical therapies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17029348     DOI: 10.3171/foc.2006.21.3.9

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  9 in total

1.  Sphingosylphosphorylcholine is a proinflammatory mediator in cerebral arteries.

Authors:  Christiane Wirrig; Irene Hunter; Fiona A Mathieson; Graeme F Nixon
Journal:  J Cereb Blood Flow Metab       Date:  2010-06-16       Impact factor: 6.200

2.  Intracisternal infusion of magnesium sulfate solution improved reduced cerebral blood flow induced by experimental subarachnoid hemorrhage in the rat.

Authors:  Kentaro Mori; Masahiro Miyazaki; Junko Iwata; Takuji Yamamoto; Yasuaki Nakao
Journal:  Neurosurg Rev       Date:  2008-02-06       Impact factor: 3.042

3.  A Highly Predictive MicroRNA Panel for Determining Delayed Cerebral Vasospasm Risk Following Aneurysmal Subarachnoid Hemorrhage.

Authors:  Wang-Xia Wang; Joe E Springer; Kevin Xie; David W Fardo; Kevin W Hatton
Journal:  Front Mol Biosci       Date:  2021-05-14

4.  Neuroprotective effect of hydrogen-rich saline against neurologic damage and apoptosis in early brain injury following subarachnoid hemorrhage: possible role of the Akt/GSK3β signaling pathway.

Authors:  Yuan Hong; AnWen Shao; Jianfeng Wang; Sheng Chen; HaiJian Wu; Devin W McBride; Qun Wu; XueJun Sun; JianMin Zhang
Journal:  PLoS One       Date:  2014-04-24       Impact factor: 3.240

5.  Comparative efficacy of meloxicam and placebo in vasospasm of patients with subarachnoid hemorrhage.

Authors:  Seyed Mohammad Ghodsi; Niayesh Mohebbi; Soheil Naderi; Mousareza Anbarloie; Ahmad Aoude; Seyed Sohail Habibi Pasdar
Journal:  Iran J Pharm Res       Date:  2015       Impact factor: 1.696

6.  Delivery of xenon-containing echogenic liposomes inhibits early brain injury following subarachnoid hemorrhage.

Authors:  Yi-Feng Miao; Tao Peng; Melanie R Moody; Melvin E Klegerman; Jaroslaw Aronowski; James Grotta; David D McPherson; Hyunggun Kim; Shao-Ling Huang
Journal:  Sci Rep       Date:  2018-01-11       Impact factor: 4.379

7.  Nitric Oxide-Based Treatment of Poor-Grade Patients After Severe Aneurysmal Subarachnoid Hemorrhage.

Authors:  Angelika Ehlert; Jitka Starekova; Gerd Manthei; Annette Ehlert-Gamm; Joachim Flack; Marie Gessert; Joachim Gerss; Volker Hesselmann
Journal:  Neurocrit Care       Date:  2020-06       Impact factor: 3.210

8.  Aneurysmal subarachnoid haemorrhage-cerebral vasospasm and prophylactic ibuprofen: a randomised controlled pilot trial protocol.

Authors:  Mojtaba Dayyani; Ermia Mousavi Mohammadi; Vahid Ashoorion; Behnam Sadeghirad; Mohammadreza Javedani Yekta; James C Grotta; Nestor R Gonzalez; Samira Zabihyan
Journal:  BMJ Open       Date:  2022-04-12       Impact factor: 2.692

9.  Estradiol reduces ferrous citrate complex-induced NOS2 up-regulation in cerebral endothelial cells by interfering the nuclear factor kappa B transactivation through an estrogen receptor β-mediated pathway.

Authors:  Li-Ching Chen; Wen-Sen Lee
Journal:  PLoS One       Date:  2013-12-23       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.